444 related articles for article (PubMed ID: 25107680)
1. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study.
Chow EPF; Tabrizi SN; Fairley CK; Wigan R; Machalek DA; Garland SM; Cornall AM; Atchison S; Hocking JS; Bradshaw CS; Balgovind P; Murray GL; Chen MY
Lancet Infect Dis; 2021 Oct; 21(10):1448-1457. PubMed ID: 34043963
[TBL] [Abstract][Full Text] [Related]
4. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
[TBL] [Abstract][Full Text] [Related]
5. Fall in human papillomavirus prevalence following a national vaccination program.
Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Cummins E; Liu B; Bateson D; McNamee K; Garefalakis M; Garland SM
J Infect Dis; 2012 Dec; 206(11):1645-51. PubMed ID: 23087430
[TBL] [Abstract][Full Text] [Related]
6. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction.
Shilling H; Garland SM; Atchison S; Cornall AM; Brotherton JML; Bateson D; McNamee K; Kaldor JM; Hocking JS; Chen MY; Fairley CK; McNulty A; Bell C; Marshall L; Ooi C; Skinner SR; Murray G; Molano M; Tabrizi S; Machalek DA
Vaccine; 2021 Aug; 39(34):4856-4863. PubMed ID: 34281743
[TBL] [Abstract][Full Text] [Related]
8. Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction.
Covert C; Ding L; Brown D; Franco EL; Bernstein DI; Kahn JA
Hum Vaccin Immunother; 2019; 15(7-8):1962-1969. PubMed ID: 30633598
[TBL] [Abstract][Full Text] [Related]
9. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.
Kavanagh K; Pollock KG; Cuschieri K; Palmer T; Cameron RL; Watt C; Bhatia R; Moore C; Cubie H; Cruickshank M; Robertson C
Lancet Infect Dis; 2017 Dec; 17(12):1293-1302. PubMed ID: 28965955
[TBL] [Abstract][Full Text] [Related]
10. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
11. Geographical disparities in human papillomavirus herd protection.
Berenson AB; Hirth JM; Chang M
Cancer Med; 2020 Jul; 9(14):5272-5280. PubMed ID: 32483924
[TBL] [Abstract][Full Text] [Related]
12. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
13. Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis.
Brotherton JM; Budd A; Rompotis C; Bartlett N; Malloy MJ; Andersen RL; Coulter KA; Couvee PW; Steel N; Ward GH; Saville M
Papillomavirus Res; 2019 Dec; 8():100177. PubMed ID: 31319173
[TBL] [Abstract][Full Text] [Related]
14. Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013.
Cameron RL; Kavanagh K; Pan J; Love J; Cuschieri K; Robertson C; Ahmed S; Palmer T; Pollock KG
Emerg Infect Dis; 2016 Jan; 22(1):56-64. PubMed ID: 26692336
[TBL] [Abstract][Full Text] [Related]
15. Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination.
Machalek DA; Garland SM; Brotherton JML; Bateson D; McNamee K; Stewart M; Rachel Skinner S; Liu B; Cornall AM; Kaldor JM; Tabrizi SN
J Infect Dis; 2018 Apr; 217(10):1590-1600. PubMed ID: 29425358
[TBL] [Abstract][Full Text] [Related]
16. Human Papillomavirus (HPV) Vaccine Effectiveness and Potential Herd Immunity for Reducing Oncogenic Oropharyngeal HPV-16 Prevalence in the United Kingdom: A Cross-sectional Study.
Mehanna H; Bryant TS; Babrah J; Louie K; Bryant JL; Spruce RJ; Batis N; Olaleye O; Jones J; Struijk L; Molijn A; Vorsters A; Rosillon D; Taylor S; D'Souza G
Clin Infect Dis; 2019 Sep; 69(8):1296-1302. PubMed ID: 30590469
[TBL] [Abstract][Full Text] [Related]
17. Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women, a population at higher risk of cervical cancer: The VIP-I study.
McGregor S; Saulo D; Brotherton JML; Liu B; Phillips S; Skinner SR; Luey M; Oliver L; Stewart M; Tabrizi SN; Garland S; Kaldor JM
Vaccine; 2018 Jul; 36(29):4311-4316. PubMed ID: 29880245
[TBL] [Abstract][Full Text] [Related]
18. HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program.
Tabrizi SN; Brotherton JM; Stevens MP; Condon JR; McIntyre P; Smith D; Garland SM;
J Clin Virol; 2014 Jul; 60(3):250-6. PubMed ID: 24854516
[TBL] [Abstract][Full Text] [Related]
19. Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination.
Markowitz LE; Naleway AL; Lewis RM; Crane B; Querec TD; Weinmann S; Steinau M; Unger ER
Vaccine; 2019 Jun; 37(29):3918-3924. PubMed ID: 31160099
[TBL] [Abstract][Full Text] [Related]
20. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.
Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM
Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
